Cargando…
Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents
BACKGROUND: In cycling tumour cells, the binary cyclin-dependent kinase Cdk4/cyclin D or Cdk2/cyclin E complex is inhibited by p21 following DNA damage to induce G1 cell-cycle arrest. However, it is not known whether other proteins are also recruited within Cdk complexes, or their role, and this was...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817341/ https://www.ncbi.nlm.nih.gov/pubmed/24104967 http://dx.doi.org/10.1038/bjc.2013.613 |
_version_ | 1782478059747672064 |
---|---|
author | He, G Kuang, J Koomen, J Kobayashi, R Khokhar, A R Siddik, Z H |
author_facet | He, G Kuang, J Koomen, J Kobayashi, R Khokhar, A R Siddik, Z H |
author_sort | He, G |
collection | PubMed |
description | BACKGROUND: In cycling tumour cells, the binary cyclin-dependent kinase Cdk4/cyclin D or Cdk2/cyclin E complex is inhibited by p21 following DNA damage to induce G1 cell-cycle arrest. However, it is not known whether other proteins are also recruited within Cdk complexes, or their role, and this was investigated. METHODS: Ovarian A2780 tumour cells were exposed to the platinum-based antitumour agent 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) (DAP), which preferentially induces G1 arrest in a p21-dependent manner. The Cdk complexes were analysed by gel filtration chromatography, immunoblot and mass spectrometry. RESULTS: The active forms of Cdk4 and Cdk2 complexes in control tumour cells have a molecular size of ∼140 kDa, which increased to ∼290 kDa when inhibited following G1 checkpoint activation by DAP. Proteomic analysis identified Cdk, cyclin, p21 and proliferating cell nuclear antigen (PCNA) in the inhibited complex, and biochemical studies provided unequivocal evidence that the increase in ∼150 kDa of the inhibited complex is consistent with p21-dependent recruitment of PCNA as a trimer, likely bound to three molecules of p21. Although p21 alone was sufficient to inhibit the Cdk complex, PCNA was critical for stabilising p21. CONCLUSION: G1 Cdk complexes inhibited by p21 also recruit PCNA, which inhibits degradation and, thereby, prolongs activity of p21 within the complex. |
format | Online Article Text |
id | pubmed-3817341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-38173412014-10-29 Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents He, G Kuang, J Koomen, J Kobayashi, R Khokhar, A R Siddik, Z H Br J Cancer Translational Therapeutics BACKGROUND: In cycling tumour cells, the binary cyclin-dependent kinase Cdk4/cyclin D or Cdk2/cyclin E complex is inhibited by p21 following DNA damage to induce G1 cell-cycle arrest. However, it is not known whether other proteins are also recruited within Cdk complexes, or their role, and this was investigated. METHODS: Ovarian A2780 tumour cells were exposed to the platinum-based antitumour agent 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) (DAP), which preferentially induces G1 arrest in a p21-dependent manner. The Cdk complexes were analysed by gel filtration chromatography, immunoblot and mass spectrometry. RESULTS: The active forms of Cdk4 and Cdk2 complexes in control tumour cells have a molecular size of ∼140 kDa, which increased to ∼290 kDa when inhibited following G1 checkpoint activation by DAP. Proteomic analysis identified Cdk, cyclin, p21 and proliferating cell nuclear antigen (PCNA) in the inhibited complex, and biochemical studies provided unequivocal evidence that the increase in ∼150 kDa of the inhibited complex is consistent with p21-dependent recruitment of PCNA as a trimer, likely bound to three molecules of p21. Although p21 alone was sufficient to inhibit the Cdk complex, PCNA was critical for stabilising p21. CONCLUSION: G1 Cdk complexes inhibited by p21 also recruit PCNA, which inhibits degradation and, thereby, prolongs activity of p21 within the complex. Nature Publishing Group 2013-10-29 2013-10-08 /pmc/articles/PMC3817341/ /pubmed/24104967 http://dx.doi.org/10.1038/bjc.2013.613 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Translational Therapeutics He, G Kuang, J Koomen, J Kobayashi, R Khokhar, A R Siddik, Z H Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents |
title | Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents |
title_full | Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents |
title_fullStr | Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents |
title_full_unstemmed | Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents |
title_short | Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents |
title_sort | recruitment of trimeric proliferating cell nuclear antigen by g1-phase cyclin-dependent kinases following dna damage with platinum-based antitumour agents |
topic | Translational Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817341/ https://www.ncbi.nlm.nih.gov/pubmed/24104967 http://dx.doi.org/10.1038/bjc.2013.613 |
work_keys_str_mv | AT heg recruitmentoftrimericproliferatingcellnuclearantigenbyg1phasecyclindependentkinasesfollowingdnadamagewithplatinumbasedantitumouragents AT kuangj recruitmentoftrimericproliferatingcellnuclearantigenbyg1phasecyclindependentkinasesfollowingdnadamagewithplatinumbasedantitumouragents AT koomenj recruitmentoftrimericproliferatingcellnuclearantigenbyg1phasecyclindependentkinasesfollowingdnadamagewithplatinumbasedantitumouragents AT kobayashir recruitmentoftrimericproliferatingcellnuclearantigenbyg1phasecyclindependentkinasesfollowingdnadamagewithplatinumbasedantitumouragents AT khokharar recruitmentoftrimericproliferatingcellnuclearantigenbyg1phasecyclindependentkinasesfollowingdnadamagewithplatinumbasedantitumouragents AT siddikzh recruitmentoftrimericproliferatingcellnuclearantigenbyg1phasecyclindependentkinasesfollowingdnadamagewithplatinumbasedantitumouragents |